Home|Journals|Articles by Year

Directory for Medical Articles
 

Open Access

Original Article



Novel glitazone attenuates rotenone-induced toxicity in mouse model of Parkinsonís disease

Ankith B. Shetty, Kamsagara Linganna Krishna, Bommenahally Ravanappa Prashantha Kumar, Hittanahalli Shivakumar Nandini.

Abstract
Parkinsonís disease (PD) is the second most common neurodegenerative disorder, and there are no drugs that will directly tackle the inflammatory component of PD. In the present study, we assessed the novel glitazone for reversal of rotenone-induced toxicity in experimental mouse model. The 14 virtual glitazone compounds were subjected to molecular docking study for target protein 3CS8; among these, compound C25 and C34 have shown better binding activity. Pharmacokinetics studies were conducted for the above compounds in rat model to chose best one for further toxicity and efficacy studies. The compound C25 showed better kinetic profile when compared to C34 and better t1/2 when compared to the standard pioglitazone. Compound C25 then tested for acute toxicity by OECD guideline 423 and evaluated for its neuroprotective activity in mouse model. The activity of the compound was assessed by the behavioral parameters on weekly intervals during the study period and estimated the antioxidant level in the brain homogenate. The compound has shown good activity dose-dependently; however, further research is required to confirm its activity and to support our hypothesis.

Key words: 3CS8, Docking, PPARő≥, Glitazones, Parkinsonism, Kinetics






Similar Articles

Full-text options


Latest Statistics about COVID-19
• pubstat.org


Add your Article(s) to Indexes
• citeindex.org






Journal Finder
Covid-19 Trends and Statistics
CiteIndex.org
CancerLine
FoodsLine
PhytoMedline
About BiblioMed
License Information
Terms & Conditions
Privacy Policy
Contact Us

The articles in Bibliomed are open access articles licensed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License (https://creativecommons.org/licenses/by-nc-sa/4.0/) which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.